-+ 0.00%
-+ 0.00%
-+ 0.00%

Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate Betabart Advancing Toward First Patient Dosing In Q1 2026

Benzinga·01/12/2026 12:07:09
Listen to the news
  • Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics
  • Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026
  • First clinical trial globally targeting B7H3 with a systemic radiopharmaceutical
  • Two additional preclinical Radiopharm Ventures' assets show early positive results with plans to move to final candidate selection in 2026